Palatin Technologies announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension." This issued patent further strengthens the company’s intellectual property position and coverage for the company’s approved therapeutic product for hypoactive sexual desire disorder in premenopausal women, Vyleesi. The patent has, with patent terms adjustments, a term through April 29, 2041. The claims of the patent relate to use of bremelanotide, marketed by the company under the trade name Vyleesi, for treatment of female sexual dysfunction in patients with controlled hypertension. The patent is solely owned by the company.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PTN:
- Palatin reports Q2 EPS (13c), consensus (70c)
- Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
- Palatin begins enrollment in Phase 2 study of diabetic kidney disease candidate
- Palatin receives $4.7M of non-dilutive funding
- Palatin’s PL8177 shows therapeutic effect in arthritis pre-clinical study